Hangzhou IVD Giant Surges 28% in 3 Days on Brain-Computer Interface Move, Adding $2.15B in Market Cap

August 13,An investor asked Biotop Biotech about the company's layout and progress in the brain-computer interface industry.？Are there any practical applications?？

Biotime Secretary of the Board：Dear Investors，Hello！The company has invested in Hangzhou Qingshi Yongjun Medical Equipment Co., Ltd. through its subsidiary Hangzhou Botai Zhitou Enterprise Management Co., Ltd.（Hereinafter referred to as“Evergreen Stone”），Post-investment share: 5%。QingStone YongJue was founded by the invasive brain-computer interface team of Zhejiang University.，Is the first technology achievement transformation enterprise of Nanhu Brain-Computer Cross Research Institute.，The company's first product targets nearly 30% of treatment-resistant severe depression patients among the global population of 300 million depression sufferers.，Through AI algorithm-equipped Class III active implantable medical devices，Provide patients with personalized、Due to illness、Personalized Treatment Plan Based on Timing。Implanting electrodes into the patient's cerebral cortex through surgical procedures，Contact brain tissue to transmit neural signals，Through implantable deep brain neurostimulation（DBS）Precise stimulation of target points to achieve the purpose of treating major diseases。It has currently entered the research-based clinical trial stage.，Has not yet obtained a medical device registration certificate。

Qing Stone Yongjuan was established in January 2025 as the first industrialized company incubated by the South Lake Brain-Computer Interdisciplinary Research Institute. It was founded by core members of Zhejiang University's invasive brain-computer interface team. The institute, a "brain-computer medicine" interdisciplinary research platform co-built by the Yuhang District Government and Zhejiang University, brings together a scientific research team of over a hundred people led by two academicians. It is equipped with advanced facilities such as animal laboratories and Class 100,000 GMP laboratories, and has established clinical cooperation platforms with the First Affiliated Hospital of Zhejiang University and the Second Affiliated Hospital of Zhejiang University. This "Institute + Company" model ensures that Qing Stone Yongjuan achieves full-chain integration from technology development to clinical transformation.

The company attracted significant attention from the capital market right after its establishment. In January 2025, it completed the first round of financing worth tens of millions of yuan, with investments from 11 institutions and individuals, including Ginkgo Valley Capital, Oufang Investment, and Yuhang State Investment. On May 20, Botop Biomedical's subsidiary Botep Zhitou strategically acquired a 5% stake, further strengthening the industrial synergy of "diagnostics + therapeutics."

The core product of Qingshi Yongjue is a closed-loop modulation system for depression based on invasive brain-computer interface technology, which includes two Class III medical devices, one artificial intelligence diagnosis and treatment software, and a cloud platform for managing the full-course data of patients. The system collects brain electrical signals in real time through implanted electrodes and dynamically adjusts neurostimulation parameters using AI algorithms to achieve closed-loop treatment of "monitoring - analysis - intervention." Notably, its self-developed active implantable device has completed animal experiments with performance meeting design standards. The first scientific research clinical trial showed significant effects, and it has now entered the type inspection phase. According to the plan, registration clinical trials will be conducted at the Second Affiliated Hospital of Zhejiang University in 2027, with commercial application expected by 2030.

Biotest Biotech was founded in 2008. It is a national high-tech enterprise specializing in the research, development, manufacturing, sales, and service of in vitro diagnostic reagents, raw materials, and instruments. Biotest Biotech is committed to providing innovative, instant, and high-quality diagnostic products and solutions to users worldwide to meet unmet medical needs. Currently, Biotest has about a hundred products, with business covering more than 100 countries and regions globally, serving over 3 billion people. The company's product range includes drug abuse testing, infectious disease testing, reproductive health testing, tumor marker testing, cardiac marker testing, and other product series, among which drug abuse testing and infectious disease testing are the leading product lines. The company now possesses over 600 rapid testing products certified by domestic and international institutions. Key performance indicators such as product specificity and sensitivity have reached advanced industry levels. Its business scope extends to many countries and regions worldwide, with overseas sales accounting for approximately 75% of the total.

In the past five years, thanks to its outstanding performance in the global fight against the pandemic, Biotest Biotech's performance has soared, and it was successfully listed on the STAR Market in 2021.